Oral Session 2-9B CML: Clinical trials

[OS2-9B-6] Efficacy and safety of first-line bosutinib vs imatinib in Asian patients in the BFORE trial

Charles Chuah¹, Liang Piu Koh², Tontanai Numbenjapon³, Dae Young Zang⁴, Kiat Hoe Ong⁵, Young Rok Do⁶, Eric Leip⁷, Chiho Ono⁸, Rocco Crescenzo⁹, Jorge Cortes¹⁰, Tim Brümmendorf¹¹, Carlo Gambacorti-Passerini¹², Michael Deininger¹³, Michael Mauro¹⁴, Andreas Hochhaus¹⁵, Dong-Wook Kim¹⁶ (1.Singapore General Hospital, Duke-NUS Medical School, Singapore, Republic of Singapore, 2.National University Cancer Institute, Singapore, Republic of Singapore, 3.Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Kingdom of Thailand, 4.Hallym University Sacred Heart Hospital, Anyang, Republic of Korea, 5.Tan Tock Seng Hospital, Singapore, Republic of Singapore, 6.Keimyung University, Daegu, Republic of Korea, 7.Pfizer Inc, Cambridge, United States of America, 8.Pfizer Japan Inc, Tokyo, Japan, 9.Pfizer Inc, Collegeville, United States of America, 10.University of Texas MD Anderson Cancer Center, Houston, United States of America, 11.Universitätsklinikum RWTH Aachen, Aachen, Federal Republic of Germany, 12.University of Milano-Bicocca, San Gerardo Hospital, Monza, Italian Republic, 13.University of Utah, Salt Lake City, United States of America, 14.Memorial Sloan Kettering Cancer Center, New York, United States of America, 15.Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Federal Republic of Germany, 16.Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea)